92945-27-2

Basic information

• Product Name: Ethyl 3-n-propylpyrazole-5-carboxylate
• Synonyms: 3-n-Propylpyrazole-5-carboxylic acid ethyl ester;3-PROPYL-1H-PYRAZOLE-5-CARBOXYLIC ACID ETHYL ESTER;ETHYL 3-N-PROPYLPYRAZOLE-5-CARBOXYLATE;1H-Pyrazol-3-Carbonsure, 5-propyl-, Ethylester;ethyl 3-n-propylpyrazole-5-carboxylate 98% 5g;Ethyl 5-n-propyl-1H-pyrazole-3-carboxylate, 98%;1H-pyrazole-3-carboxylic acid, 5-propyl-, ethyl ester;ethyl 3-n-propylpyrazole-5-carboxylate 98%
• CAS NO: 92945-27-2
• Molecular Formula: C₉H₁₄N₂O₂
• Molecular Weight: 182.22
• Mol File: 92945-27-2.mol
• Article Data: 17

Chemical Properties

• Melting Point: 48-50°C
• Boiling Point: 331.1 °C at 760 mmHg
• Flash Point: 154 °C
• Appearance: /
• Density: 1.106 g/cm³
• Storage Temp.: 2-8°C
• PKA: 11.52±0.10(Predicted)
• BRN: 7634535
• CAS DataBase Reference: Ethyl 3-n-propylpyrazole-5-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 3-n-propylpyrazole-5-carboxylate(92945-27-2)
• EPA Substance Registry System: Ethyl 3-n-propylpyrazole-5-carboxylate(92945-27-2)

Safety Data

• Safety Statements: 22-24/25
• HazardClass: IRRITANT
• Hazardous Substances Data: 92945-27-2(Hazardous Substances Data)

Usage

Uses

Ethyl 5-Propyl-1H-pyrazole-3-carboxylate is an intermediate in the synthesis of pyrazoles and diazoacetates which act as antioxidants inhibitors with varying levels pharmaceutical activity.

Upstream product

• 36983-31-0 ethyl 3-butyrylpyruvate 
• 107-87-9 2-Pentanone 
• 95-92-1 oxalic acid diethyl ester 
• 623-73-4 diazoacetic acid ethyl ester 
• 627-19-0 1-Pentyne 
• 76424-47-0 3-n-propyl-1H-pyrazolo-5-carboxylic acid 
• 110-62-3 pentanal 
• 942040-13-3 C₈H₁₆N₂O₂ 
• 80540-58-5 2,4-dioxoheptanoic acid ethyl ester 
• 1537177-57-3 C₁₁H₁₇NO₆ 
• 1576-35-8 toluene-4-sulfonic acid hydrazide 

Downstream Products

• 133261-07-1 1-Methyl-3-n-propylpyrazole-5-carboxylic acid ethyl ester 
• 957129-48-5 5-n-propyl-1H-pyrazole-3-carboxylic acid amide 
• 1610875-93-8 1-methyl-3-propyl-5-(2,4,5-trimethoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7-(6H)-one 

Relevant articles and documents

NOVEL COMPOUNDS FOR USE IN COGNITION IMPROVEMENT

Novel compounds for use in cognition improvement It relates to certain compounds having a polycyclic structure and a -(C=O)NRaRb moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurodegenerative diseases.

Novel pyrazole-5-carboxamide and pyrazole-pyrimidine derivatives: Synthesis and anticancer activity

A series of novel pyrazole-5-carboxamide and pyrazole-pyrimidine derivatives were designed and synthesized. All compounds have been screened for their antiproliferative activity against MGC-803, SGC-7901 and Bcap-37 cell lines in vitro. The results revealed that compounds 8a, 8c and 8e exhibited strong inhibitory activity against MGC-803 cell line. The flow cytometric analysis result showed that compound 8e could inhibit MGC-803 proliferation. Some title compounds were tested against telomerase, and compound 8e showed the most potent inhibitory activity with IC50 value at 1.02 ± 0.08 μM. The docking simulation of compound 8e was performed to get the probable binding model, among them, LYS 189, LYS 372, LYS 249 and ASP 254 may be the key residues for the telomerase activity.

NOVEL COMPOUNDS AS DUAL INHIBITORS OF PHOSPHODIESTERASES AND HISTONE DEACETYLASES

It relates to certain compounds having a polycyclic structure and a hydroxamic acid moiety, wherein the polycyclic structure comprises at least three ring systems, wherein one ring system is a polycyclic ring system comprising from 2 to 4 rings; at least one ring is an aromatic ring; and wherein the structure comprises at least 3 nitrogen atoms and 1 oxygen atom. It also relates to a process for their preparation, as well as to pharmaceutical compositions containing them, and to their use in medicine, in particular in the treatment and/or prevention of neurological disorders coursing with a cognition deficit or impairment, or neurodegenerative diseases. wherein B1 is a radical selected from the group consisting of formula (A"), formula (B"), formula (C"), and formula (D"):